Aurinia Pharmaceuticals (AUPH) Total Non-Current Liabilities (2016 - 2024)

Aurinia Pharmaceuticals has reported Total Non-Current Liabilities for 9 years, with the latest figure at $162.1 million in Q4 2024.

• For the quarter ending Q4 2024, Total Non-Current Liabilities rose 1.8% year-over-year to $162.1 million; the trailing twelve-month figure through Dec 2024 stood at $162.1 million (up 1.8% YoY), and the FY2024 full-year result was $162.1 million, up 1.8% from the prior year.
• Total Non-Current Liabilities for Q4 2024 stood at $162.1 million, up from $150.5 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $162.1 million in Q4 2024, with the low at $29.0 million in Q1 2021.
• Historically, Total Non-Current Liabilities has averaged $88.2 million across 5 years, with a median of $49.1 million in 2023.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 251.47% — and 2024, when it fell 1.52%.
• Aurinia Pharmaceuticals' Total Non-Current Liabilities stood at $39.6 million in 2020, then gained by 21.99% to $48.3 million in 2021, then increased by 10.21% to $53.3 million in 2022, then soared by 198.91% to $159.2 million in 2023, then rose by 1.8% to $162.1 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $162.1 million (Q4 2024), $150.5 million (Q3 2024), and $148.0 million (Q2 2024), per Business Quant data.